These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 16410449)

  • 1. Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML.
    Reindl C; Bagrintseva K; Vempati S; Schnittger S; Ellwart JW; Wenig K; Hopfner KP; Hiddemann W; Spiekermann K
    Blood; 2006 May; 107(9):3700-7. PubMed ID: 16410449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.
    Choudhary C; Schwäble J; Brandts C; Tickenbrock L; Sargin B; Kindler T; Fischer T; Berdel WE; Müller-Tidow C; Serve H
    Blood; 2005 Jul; 106(1):265-73. PubMed ID: 15769897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
    Marhäll A; Heidel F; Fischer T; Rönnstrand L
    Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From kinases to cancer: leakiness, loss of autoinhibition and leukemia.
    Reindl C; Spiekermann K
    Cell Cycle; 2006 Mar; 5(6):599-602. PubMed ID: 16582613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor.
    Breitenbuecher F; Schnittger S; Grundler R; Markova B; Carius B; Brecht A; Duyster J; Haferlach T; Huber C; Fischer T
    Blood; 2009 Apr; 113(17):4074-7. PubMed ID: 18483393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.
    Grundler R; Thiede C; Miething C; Steudel C; Peschel C; Duyster J
    Blood; 2003 Jul; 102(2):646-51. PubMed ID: 12663439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.
    Jiang J; Paez JG; Lee JC; Bo R; Stone RM; DeAngelo DJ; Galinsky I; Wolpin BM; Jonasova A; Herman P; Fox EA; Boggon TJ; Eck MJ; Weisberg E; Griffin JD; Gilliland DG; Meyerson M; Sellers WR
    Blood; 2004 Sep; 104(6):1855-8. PubMed ID: 15178581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
    Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
    Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells.
    Bagrintseva K; Schwab R; Kohl TM; Schnittger S; Eichenlaub S; Ellwart JW; Hiddemann W; Spiekermann K
    Blood; 2004 Mar; 103(6):2266-75. PubMed ID: 14604974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).
    Kindler T; Breitenbuecher F; Kasper S; Estey E; Giles F; Feldman E; Ehninger G; Schiller G; Klimek V; Nimer SD; Gratwohl A; Choudhary CR; Mueller-Tidow C; Serve H; Gschaidmeier H; Cohen PS; Huber C; Fischer T
    Blood; 2005 Jan; 105(1):335-40. PubMed ID: 15345593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.
    Rocnik JL; Okabe R; Yu JC; Lee BH; Giese N; Schenkein DP; Gilliland DG
    Blood; 2006 Aug; 108(4):1339-45. PubMed ID: 16627759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591.
    Vempati S; Reindl C; Wolf U; Kern R; Petropoulos K; Naidu VM; Buske C; Hiddemann W; Kohl TM; Spiekermann K
    Clin Cancer Res; 2008 Jul; 14(14):4437-45. PubMed ID: 18628457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model.
    Grundler R; Miething C; Thiede C; Peschel C; Duyster J
    Blood; 2005 Jun; 105(12):4792-9. PubMed ID: 15718420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.
    Tse KF; Allebach J; Levis M; Smith BD; Bohmer FD; Small D
    Leukemia; 2002 Oct; 16(10):2027-36. PubMed ID: 12357354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3).
    Murata K; Kumagai H; Kawashima T; Tamitsu K; Irie M; Nakajima H; Suzu S; Shibuya M; Kamihira S; Nosaka T; Asano S; Kitamura T
    J Biol Chem; 2003 Aug; 278(35):32892-8. PubMed ID: 12815052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia.
    Janke H; Pastore F; Schumacher D; Herold T; Hopfner KP; Schneider S; Berdel WE; Büchner T; Woermann BJ; Subklewe M; Bohlander SK; Hiddemann W; Spiekermann K; Polzer H
    PLoS One; 2014; 9(3):e89560. PubMed ID: 24608088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3.
    Spiekermann K; Dirschinger RJ; Schwab R; Bagrintseva K; Faber F; Buske C; Schnittger S; Kelly LM; Gilliland DG; Hiddemann W
    Blood; 2003 Feb; 101(4):1494-504. PubMed ID: 12406902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential signaling of Flt3 activating mutations in acute myeloid leukemia: a working model.
    Chan PM
    Protein Cell; 2011 Feb; 2(2):108-15. PubMed ID: 21359601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248).
    Schittenhelm MM; Yee KW; Tyner JW; McGreevey L; Haley AD; Town A; Griffith DJ; Bainbridge T; Braziel RM; O'Farrell AM; Cherrington JM; Heinrich MC
    Leukemia; 2006 Nov; 20(11):2008-14. PubMed ID: 16990784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mutational spectrum of FLT3 gene in acute lymphoblastic leukemia is different from acute myeloid leukemia.
    Zhang Y; Zhang Y; Wang F; Wang M; Liu H; Chen X; Cao P; Ma X; Teng W; Zhang X; Liu H
    Cancer Gene Ther; 2020 Feb; 27(1-2):81-88. PubMed ID: 31285539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.